annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Discussion
11:30 AM Sergio Giralt, MD (Abstracts #8017–8018)
University of Texas M. D. Anderson Cancer Center
Post-transplant Maintenance Therapies
11:45 AM Defining the prognostic variables in gene expression profiling (GEP)-defined
high-risk multiple myeloma (MM): Distinguishing early failures (EF) from
sustained control (SC). (Abstract #8019)
B. Barlogie, J. D. Shaughnessy, J. Haessler, A. Hoering, F. Van Rhee,
E. J. Anaissie, J. Crowley
12:00 PM Elotuzumab in combination with lenalidomide and low-dose dexamethasone
in relapsed or refractory multiple myeloma: A phase I/II study. (Abstract
#8020)
S. Lonial, R. Vij, J. Harousseau, T. Facon, P. Moreau, X. Leleu, C. Westland,
A. K. Singhal, S. Jagannath, Multiple Myeloma Research Consortium
12:15 PM Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in
patients (Pts) with multiple myeloma (MM): Results of the Medical Research
Council (MRC) Myeloma IX Study. (Abstract #8021)
G. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy,
M. Drayson, R. G. Owen, G. H. Jackson, J. A. Child
235
SUNDAY